NEW YORK (GenomeWeb) – Signal Genetics said in its Form 10-K today that its full-year 2014 revenue growth was flat year over year at $4.3 million. 

The molecular diagnostics firm also said that its net loss attributable to shareholders and company members was $7.9 million in 2014, compared to a net loss of $2.4 million in 2013. On a per-share basis, net loss retreated to $3.50 in 2014 compared to $12.23 in 2013. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.